|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
19 DRESS and 67 SJS/TEN) and 182 allopurinol-tolerant patients were enrolled in the study.The HLA-B*58:01 allele was determined.
|
28509689 |
2017 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN.
|
18192896 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*5901 exhibited a high odds ratio for SJS/TEN with ocular complications.
|
18385790 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*5901 may be a useful screening marker for predicting methazolamide-induced SJS/TEN in patients of Korean and Japanese ancestry.
|
20504258 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*1502 genotyping with sequence-specific primer polymerase chain reaction (PCR-SSP) and PCR-sequencing based typing (PCR-SBT) was performed on 17 CBZ-induced SJS/TEN patients, 21 CBZ-tolerant controls, and 185 healthy controls recruited during 2008-2010.
|
21424386 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HLA-B*44:03 was also detected as an independent risk allele for CM-, including AR-SJS/TEN with SOC.
|
24781922 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.
|
25266342 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 for carbamazepine-induced SJS/TEN and HLA-B*58:01 for allopurinol-induced SCAR), involvement of specific TCR, induction of T-cell-mediated responses (e.g. granulysin, Fas ligand, perforin/granzyme B and T-helper 1/2-associated cytokines) and cell death mechanism (e.g. miR-18a-5p-induced apoptosis; annexin A1 and formyl peptide receptor 1-induced necroptosis in keratinocytes).
|
27154258 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*58:01 screening-guided therapy may mitigate the risk of allopurinol-induced SJS/TEN.
|
29176400 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.
|
29642234 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A decision tree model was constructed to incorporate the real-world data on AED prescription patterns, incidences of AED-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), costs of AED treatments, SJS/TEN treatment, and HLA-B*15:02 testing, and quality of life.
|
26888992 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
A total of 461 patients would need to be screened for HLA-B*1502 to prevent one episode of SJS/TEN.
|
23132554 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Additionally, 17 of 49 patients with CM-SJS/TEN with SOC (34.7%) significantly harboured the HLA-B*44:03 and HLA-C*07:01 haplotype compared with only 11 of 159 healthy controls (6.9%) (OR=7.1, p=5.5×10<sup>-6</sup>).
|
29706602 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Allergic drug reactions are unpredictable; nevertheless, there is increased risk of drug hypersensitivity in (1) patients with cystic fibrosis who receive antibiotics; (2) patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) who receive trimethoprim-sulfamethoxazole or if human leukocyte antigen (HLA)-B*5701+ and receive the antiretroviral agent abacavir; (3) other genetically susceptible populations, e.g., Han-Chinese with HLA-B*1502+ who develop Stevens-Johnson syndrome and toxic epidermal necrolysis from carbamazepine, with HLA-B*5801+ who are at increased risk for such reactions from allopurinol, those with HLA-A*32:01 and receive vancomycin and develop drug reaction with eosinophilia and systemic symptoms syndrome; and (4) patients with a history of compatible allergic reactions to the same medication, similar class, or potentially unrelated medication.
|
31690398 |
2019 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allopurinol is an efficacious urate-lowering therapy (ULT), but is associated with rare serious adverse drug reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), with higher risk among HLA-B*5801 carriers.
|
26554739 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allopurinol-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) is strongly associated with HLA-B*58:01 in various populations including Japanese.
|
22277675 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Among the severe cADRs, HLA-B*57:01(OR = 11.00 95% CI: 1.41-85.81) and HLA-DRB1*07:01 (OR = 7.25; 95% CI: 1.09-48.18) were noted to be significantly associated with CBZ-induced Stevens Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN); HLA-B *51:01 was associated with drug reaction eosinophilia and systemic symptoms (DRESS) caused by PHT (OR = 6.90; 95% CI: 1.38-34.29).
|
30826555 |
2019 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Asians who carry the HLA-B*1502 allele have an elevated risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with the antiepileptic drugs (AEDs) carbamazepine (CBZ) and phenytoin (PHT).
|
22955130 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.
|
19915237 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities.
|
24777842 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Available data also suggest that HLA-B*1502 is a risk allele for SJS/TEN caused by other aromatic AEDs with a similar structure to CBZ.
|
20001755 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
|
18855540 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
|
18855540 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Carbamazepine-induced SJS-TEN is strongly associated with the HLA-B*1502 allele.
|
21428768 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Combining the data with previous studies, there was no significant difference in the frequency of subjects with HLA-B*1502 between the LTG-induced SJS/TEN group and the LTG-tolerant group (p = 0.08, OR 4.23, 95% CI 0.94-18.97).
|
21306565 |
2011 |